ACUMEN PHARMACEUTICALS INC (ABOS)
US00509G2093 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.7M | 1.44M -15.29% | -100.00% | 13.53M | 52.11M 285.14% | 163.88M 214.49% | 280.7M 71.28% | 485.68M 73.02% | |||||||
| EBITDA YoY % growth | N/A | N/A | -16.395M | -41.206M -130.90% | -58.074M -35.10% | -108.059M -76.92% | -136.517M -26.34% | -118.922M 12.89% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.81M | -7.91M -1.28% | -37.949M -147.53% | -42.101M -131.05% | -59.947M -35.14% | -105.903M -73.22% | -127.697M -20.58% | -133.607M -4.63% | -170.654M -27.73% | -129.534M 24.10% | -114.039M 11.96% | -36.598M 67.91% | 47.864M 230.78% | 217.67M 354.77% | |
| Operating Margin | -459.41% | -549.31% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -957.38% | -218.84% | -22.33% | 17.05% | 44.82% | |
| EPS YoY % growth | N/A | N/A | -3.78 | -1.00 71.98% | -1.09 -1.89% | -1.61 -49.22% | -1.90 -17.59% | -1.98 -4.68% | -2.00 -0.77% | -1.86 7.14% | -1.69 8.79% | 0.04 102.41% | 0.98 2,300.00% | 2.47 152.08% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.49 -74.86% | -0.47 -89.72% | -0.50 -47.00% | -0.53 -5.06% | -0.51 -4.17% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -32.212M -74.83% | -33.456M -88.40% | -34.986M -43.69% | -36.72M -13.98% | -38.454M -19.38% |
| EBIT Q2Q % growth | -31.275M -69.18% | -31.588M -77.72% | -33.061M -35.60% | -34.605M -7.25% | -36.222M -15.82% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.50 -108.33% | -0.37 | -0.13 | -34.30% |
| Q2 2024 Q2Q % growth | -0.34 -21.43% | -0.29 | -0.05 | -19.05% |
| Q1 2024 Q2Q % growth | -0.25 10.71% | -0.27 | 0.02 | 5.73% |
| Q4 2023 Q2Q % growth | -0.28 12.50% | -0.27 | -0.01 | -5.58% |
| Q3 2023 Q2Q % growth | -0.24 7.69% | -0.27 | 0.03 | 11.54% |
| Q2 2023 Q2Q % growth | -0.28 -12.00% | -0.35 | 0.07 | 20.66% |
| Q1 2023 Q2Q % growth | -0.28 -21.74% | -0.35 | 0.07 | 20.66% |
| Q4 2022 Q2Q % growth | -0.32 23.08% | -0.26 | -0.06 | -22.84% |
| Q3 2022 Q2Q % growth | -0.26 -160.00% | -0.23 | -0.03 | -10.92% |
| Q2 2022 Q2Q % growth | -0.25 96.84% | -0.25 | 0.00 | -0.04% |
| Q1 2022 Q2Q % growth | -0.23 | -0.17 | -0.06 | -35.84% |
| Q4 2021 Q2Q % growth | -0.42 | -0.14 | -0.27 | -187.21% |
| Q3 2021 Q2Q % growth | -0.10 | -0.17 | 0.07 | 42.44% |
| Q2 2021 Q2Q % growth | -7.91 | -4.65 | -3.26 | -70.21% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2021 Q2Q % growth | -100.00% | % | ||
| Q3 2021 Q2Q % growth | -100.00% | % | ||
| Q2 2021 Q2Q % growth | -100.00% | % | ||
| Q1 2021 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -48.15% | 0% | -19.55% |
| Revenue | N/A | N/A | N/A | N/A |